5-azacitidine in chronic myelomonocytic leukaemia (CMML): a two stage phase II, non-randomised, single arm, multi-centre, prospective trial.

Trial Profile

5-azacitidine in chronic myelomonocytic leukaemia (CMML): a two stage phase II, non-randomised, single arm, multi-centre, prospective trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2014

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Chronic myelomonocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CMML201
  • Most Recent Events

    • 01 May 2013 Status changed from active, no longer recruiting to completed, according to ISRCTN: Current Controlled Trials
    • 30 Mar 2011 United Kingdom Clinical Research Network reports accrual to date changed from 80% to 106%.
    • 14 Apr 2010 Status changed from not yet recruiting to recruiting as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top